Lilly 3Q

Lilly 3Q10

3Q10 Revenues: $5.7 billion (+2%)

3Q10 Earnings: $1.3 billion (+38%)

YTD Revenues: $16.9 billion (+6%)

YTD Earnings: $3.9 billion (+10%)

Comments: For the quarter, Zyprexa sales dropped 1% to $1.2 billion, Cymbalta sales were up 4% to $825 million, and Alimta sales rose 21% to $560 million. Strattera sales fell 12% to $128 million. The company faced a number of setbacks during the quarter, including patent invalidations of Strattera and Gemzar (both under appeal), and pipeline problems. Bydureon, the once-weekly diabetes injectable developed with Amylin and Alkermes, received a complete response letter, likely pushing approval of that product off until 2012. Type 1 diabetes treatment teplizumab, developed with MacroGenics, did not hit efficacy endpoints in its Phase III trial, and other trials have been shut down. The company also cancelled development of Alzheimer’s treatment semagacestat, after failed Phase III trials.